# Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Source: https://onco.cc/trials/nct03980041/  
OnCo record `nct03980041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Eganelisib run by Infinity Pharmaceuticals, Inc., completed.

## Summary

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) is a phase 2 interventional study registered as NCT03980041 by Infinity Pharmaceuticals, Inc., with 49 participants enrolled, started 2019-09-25. Conditions recorded: Bladder Cancer, Urothelial Carcinoma, Solid Tumor and Advanced Cancer. Interventions recorded: IPI-549 (eganelisib), Nivolumab and Placebos.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03980041
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naïve, Advanced Urothelial Carcinoma
- Sponsor: Infinity Pharmaceuticals, Inc.
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT03980041: https://clinicaltrials.gov/study/NCT03980041

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Eganelisib](https://onco.cc/drugs/eganelisib/)
- companies: [Stelexis BioSciences](https://onco.cc/companies/stelexis-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct03980041.json